关键词: 脑梗死, 阿托伐他汀, 尤瑞克林, NIHSS评分, 氧化低密度脂蛋白, 超敏C反应蛋白

Abstract: Objective  To observe the effects of ureklin combined with atorvastatin on clinical efficacy,  oxidized lowdensity lipoprotein (oxLDL) and hypersensitive creactive protein (hsCRP) in patients with acute cerebral infarction (ACI).Methods  A total of 120 ACI patients with aortic atherosclerosis but without thrombolysis and thrombectomy according to TOAST classification were randomly divided into control group and observation group,  60 cases in each group. Routine treatment was given to two groups,  including antiplatelet,  neuroprotective agents and drugs that improved blood circulation. The control group was treated with atorvastatin (20 mg/time) and qn. The observation group was treated with atorvastatin(20 mg),  qn and ureklin,  0.15 PNA,  0.9% normal saline(100  ml) and qd. Both groups were continuously treated for 2 weeks. The National Institutes of Health Stroke Scale (NIHSS) was used to evaluate the clinical efficacy before and 14 days after the treatment. The oxLDL,  hsCPR content were determined before and 14 days after the treatment. Results   After 14 days of treatment,  oxLDL and hsCRP levels in observation group were significantly lower than those in control group (P<0.01). The NIHSS scores in both groups before the treatment were lower than before (P<0.05),  and the score of  observation group was significantly lower than that of  control group (P<0.05). The clinical efficacy of  observation group was better than that of  control group (P<0.05).  Conclusion  Ureklin combined with atorvastatin in the treatment of ACI patients without thrombolysis and thrombectomy can effectively improve the nerve function defect,  promote the recovery of nerve function,  and its effect is obviously superior to routine treatment.

Key words: brain infarction, atorvastatin, ureklin, NIHSS score, oxidized lowdensity lipoprotein, hypersensitive creactive protein